NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

Inclusion Criteria:

1. Subjects ≥ 50 and ≤ 89 years of age with a diagnosis of active subfoveal CNVsecondary to wAMD in the Study Eye

2. BCVA between 20/40 and 20/400 in the Study Eye, with BCVA decrement primarilyattributable to wAMD

3. Administration of at least 3 anti-VEGF (vascular endothelial growth factor)injections in the study eye in the past 6 months for clinically active wAMD, themost recent of which was within 1 month prior to Screening Day -14 (Visit 1).

4. Must be pseudo phakic (status post cataract surgery) in the Study Eye

5. Female and Male reproductive status: Female subjects must be either: (1) ofnon-childbearing potential; or (2) of childbearing potential and using an acceptablemethod of birth control with a negative pregnancy test. Male subjects agree torefrain from sperm donations and practice contraception to avoid any pregnancy for 3months after administration of NG101.

6. Normal blood pressure (BP) and heart rate (HR), or near normal BP and HR notconsidered clinically significant (NCS) by the Investigator at the Screening Day -14 (Visit 1) and Day -7 (Visit 2)

7. Willing and able to provide written, signed informed consent after the nature of thestudy has been explained and prior to the performance of any study-relatedprocedures

8. Willingness and ability to comply with schedule for follow-up visits andpostoperative evaluations

Exclusion Criteria:

1. CNV or macular edema in the Study Eye secondary to any causes other than AMD

2. Any condition preventing visual acuity improvement in the Study Eye, e.g., fibrosis,atrophy, or retinal pigment epithelial tear involving the center of the macula

3. Any ophthalmic condition that precludes adequate ophthalmic examination or requirestreatment

4. Retinal detachment or history of retinal detachment in the Study Eye

5. Active uncontrolled glaucoma with intraocular pressure (IOP) ≥ 30 mmHg despitetreatment with more than 2 glaucoma medications, advanced glaucoma with cup-to-discratio of ≥ 0.9, visual field defects secondary to glaucoma that involve the macula,and/or optic atrophy from glaucoma

6. History of intravitreal therapy in the Study Eye, such as intravitreal steroidinjection or an investigational product, other than anti-VEGF therapy, in the 6months prior to Screening

7. History of vitrectomy, trabeculectomy, glaucoma tube-shunt procedure, minimallyinvasive glaucoma surgery (MIGS) device, or other filtration surgery in the StudyEye

8. Photodynamic therapy or retinal laser for the treatment of wAMD within the last 6months

9. Any prior therapeutic radiation in the region of the Study Eye such as whole brainradiation, proton beam radiation, gamma knife treatment, or plaque brachytherapy

10. Any previous intraocular or refractive surgery on the Study Eye within 6 months

11. Any previous gene therapy in the Study Eye

12. Presence of an ocular implant in the Study Eye at Screening, excluding intraocularlens and custom flex iris prosthesis

13. Any diabetic retinopathy or other retinal vascular disease including retinal veinocclusion, retinal artery occlusion, retinal arterial macro aneurysm, ocularischemic syndrome, retinal vasculitis, vitritis, posterior uveitis

14. Medically uncontrolled diabetes, defined as HbA1C > 8.0

15. History of ocular melanoma

16. History of any known inherited retinal disease

17. Currently taking any anticoagulant therapy, which is deemed medically necessary andcannot be permanently stopped at least 2 weeks prior to NG101 injection, excludingprophylactic low-dose aspirin therapy

18. Any underlying systemic diseases as unstable or severe cardiovascular,cerebrovascular, dementia or neurodegenerative diseases of a level that preventsadequate evaluation of the subject during the study, active malignancy or currentlyundergoing treatment for active malignancy at Screening or a history of malignancythat precludes completion of this 260 week study, and immunocompromised conditionsand/or need for immunosuppressive therapy

19. Active hepatitis B or C

20. History of human immunodeficiency virus (HIV), active tuberculosis, and/or syphilis

21. Any significant illness that would preclude study compliance and follow-up

22. Subjects who, in the Investigator's opinion, lack the mental capacity to providewritten informed consent for study participation